AstraZeneca unit debuts new open innovation platform for partnering programs

25 March 2014

Anglo-Swedish drug major AstraZeneca’s IMED Biotech unit has launched a dedicated web site to support an increasing range of open innovation programs and to better facilitate research collaborations with academia, industry, non-governmental organizations (NGOs) and governments.

The new Open Innovation website is designed to make it easy for scientists to access AstraZeneca’s collaboration and partnering programs, which include:

Clinical Compound Bank of patient-ready ‘live’ and discontinued small molecule compounds and biologics that have shown in clinical trials evidence of human target coverage and tolerability. These are being offered for novel clinical and translational research.
Pharmacology Toolbox, which comprises compounds with optimized pharmacological properties. These compounds are being made available for preclinical research to explore novel disease biology and advance scientific knowledge.
Target Innovation collaborations to enable investigators to validate novel molecular, drug targets, which could include the availability of high throughput screening capabilities.
New Molecule Profiling via advanced cheminformatic capabilities to explore the properties and therapeutic innovation potential of new molecules.
A new R&D Challenge program through which researchers can suggest solutions to specific R&D challenges faced by AstraZeneca scientists in ongoing projects.
A Suggestion Box for researchers to offer, and be rewarded for, broader innovative ideas and solutions to ongoing challenges.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK